Advancing Gut Microbiome Therapeutics

Targeting pathogen-specific diseases, addressing unmet medical needs.

Overview

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial-resistance (AMR). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).

Synthetic Biologics, Inc

Our Lead Candidates

SYN-004 (ribaxamase)

Designed to be co-administered with IV beta-lactam antibiotics, ribaxamase is an oral enzyme tablet that allows the IV antibiotic to treat the infection, while protecting the gut microbiome and preventing C. difficile infection.

View SYN-004 (ribaxamase)

SYN-010

SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is designed to reduce the body’s natural methane production in the intestine, curbing IBS-C.

View SYN-010

Protecting the Gut Microbiome

Your body has 10 times as many microbe cells as human cells.
We’re leveraging the microbiome to radically change today’s medicine.

Watch Video

tech video

How SYN-004 (ribaxamase) Works

SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract.

Watch Video

tech video

How SYN-010 Works

SYN-010 is intended to act primarily in the intestinal lumen while avoiding systemic absorption, thereby targeting the major cause of IBS-C, not just the symptoms.

Leadership

Our experienced management team has an extensive clinical and commercial track record.